Review summary
Historical dates
January 17, 1706 – April 17, 1790Synthetic DOB
1706-01-17Index visit
1782-03-02 at age 76Synthetic MRN
HR-EN004-SYN-TDTeaching objective: Manage recurrent gout in a 76-year-old man with stage 3a chronic kidney disease by the 1776 ACR treat-to-target approach (allopurinol started low and titrated to a serum urate below 6 mg/dL, colchicine prophylaxis, a thiazide replaced by losartan), and evaluate a bladder stone with imaging, cystoscopy, and flow studies, treating its outlet-obstruction cause and preventing uric acid stones with fluids, urinary alkalinization, and metabolic testing, while following the CMID kidney, blood pressure, and prostate schedules.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 17, 1706 (January 6, 1706, Old Style) | Born in Boston. | CLM-0001 |
| 1724 | Works as a compositor in London and feels pain in the bones of his hand over heated type. | CLM-0002 |
| February 1727 (1726/7 Old Style) | Pleurisy that very nearly carried him off. | CLM-0010 |
| 1735 | Severe pleurisy ending in an abscess of the left lung. | CLM-0011 |
| October 22, 1780 | Writes the Dialogue between Franklin and the Gout during a gout attack. | CLM-0005 |
| March 12, 1781 | Writes to Congress that a long and severe fit of gout the previous winter has shaken him. | CLM-0006 |
| About 1781 | First symptoms of the calculous complaint (bladder stone). | CLM-0007 |
| May 23, 1785 | Writes that he is subject to the gout and the stone. | CLM-0008 |
| April 15, 1787 | Writes that the stone has increased. | CLM-0009 |
| 1789 to 1790 | Confined chiefly to bed by the stone for his last twelve months, taking laudanum for the worst pain. | CLM-0014 |
| April 17, 1790 | Died in Philadelphia after a febrile chest illness. | CLM-0015 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Benjamin Franklin was born in Boston on January 17, 1706 (New Style); an editor's note to his autobiography gives the date as Sunday, January 6, old style, 1706, in a house on Milk Street. | confirmed | Benjamin Franklin (biography) supports Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports |
| D | In a letter of July 31, 1786, Franklin recalled that in 1724, as a compositor at Palmer's printing house in London, he sometimes heated his case of type before the fire to warm his hands, until an old workman warned him he might lose the use of his hands, and that he had felt a kind of obscure pain in the bones of his hand when working over very hot type. His own account of occupational exposure to heated type metal, which contains lead. |
confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 2. London; 1806 supports |
| D | A 2008 review of his medical history by Finger and Hagemann concluded that he suffered repeated attacks of gout and a large bladder stone, which caused considerable pain and markedly decreased his mobility. | confirmed | Finger S, Hagemann IS. Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning. Proc Am Philos Soc. 2008;152(2):189-206 supports The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports |
| R | The same review argues that several factors that raise uric acid converged in him, including sex, genetics, diet, drinking, advanced age, psoriasis, and possible lead poisoning from lead exposure. A retrospective interpretation; lead poisoning is not documented as a diagnosis in his lifetime. |
possible | Finger S, Hagemann IS. Benjamin Franklin's risk factors for gout and stones: from genes and diet to possible lead poisoning. Proc Am Philos Soc. 2008;152(2):189-206 supports |
| D | Franklin wrote the Dialogue between Franklin and the Gout, headed Midnight, October 22, 1780, in which the Gout tells him he has eaten and drunk too freely and indulged his indolence; a 2023 rheumatology review states that he woke with a gout attack that night. | confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 3. London; 1806 supports Mikhael M, Siva C. "Dialogue Between Franklin and the Gout" Reexamined. Clin Med Res. 2023;21(4):196-200. doi:10.3121/cmr.2023.1833 supports |
| D | In a letter from Passy dated March 12, 1781, to Samuel Huntington, President of Congress, Franklin wrote that he had passed his seventy-fifth year and that the long and severe fit of the gout he had the last winter had shaken him exceedingly, leaving him far from his former bodily strength. | confirmed | Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports |
| D | The 1806 edition of his works states that he had been little subject to disease, except an attack of the gout occasionally, until about the year 1781, when he was first attacked with symptoms of the calculous complaint, which continued during his life. Calculous complaint means stone; his later letters identify it as the stone. |
confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports |
| D | In a letter from Passy dated May 23, 1785, to George Wheatley, Franklin agreed that the gout is bad and the stone is worse, and wrote that at fourscore he found himself subject to the gout and the stone. | confirmed | Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports |
| D | Writing from Philadelphia on April 15, 1787, he said he had never had the least doubt that his malady was the stone, that it had increased but gave him no more pain than at Passy, and that he thought himself favored to have only the stone and gout; in a letter of October 24, 1788, he wrote that he was recovering from a long-continued gout. | confirmed | Memoirs of Benjamin Franklin; Written by Himself, Volume 2. New York: Harper & Brothers supports |
| D | In his autobiography Franklin wrote that at the beginning of February 1726/7 he was taken ill with a pleurisy that very nearly carried him off. | confirmed | Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports |
| D | The 1806 edition of his works adds that in 1735 he had a severe pleurisy that ended in an abscess of the left lobe of his lungs, and that a second similar attack some years later left no lasting effect on his breathing. | confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports |
| D | His autobiography records that he never knew his father or mother to have any sickness but that of which they died, his father Josiah at 89 in 1744 and his mother Abiah at 85 in 1752. The causes of death are not recorded in the source. |
confirmed | Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports |
| D | Franklin wrote that in 1736 he lost a son, a boy of four, to smallpox taken in the common way, and regretted that he had not had him inoculated. | confirmed | Franklin B. Autobiography of Benjamin Franklin (edited, with notes) supports |
| D | His physician's account of his last illness states that the stone had for the last twelve months confined him chiefly to his bed, and that during the most painful paroxysms he took large doses of laudanum. | confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports |
| D | About sixteen days before his death he developed a fever, then pain in the left side of the chest with cough and labored breathing; an abscess in his lungs burst, and he died in Philadelphia at about eleven at night on April 17, 1790, aged 84. The contemporary account is reported as written; the modern cause cannot be determined. |
confirmed | The Complete Works in Philosophy, Politics and Morals of the late Dr. Benjamin Franklin, Volume 1. London: Longman, Hurst, Rees, and Orme; 1806 supports Benjamin Franklin (biography) supports |
| R | A 2023 review describes him as overweight and as probably having had consequences of the metabolic syndrome, including gout. Retrospective interpretation; no measured weight is used. |
possible | Mikhael M, Siva C. "Dialogue Between Franklin and the Gout" Reexamined. Clin Med Res. 2023;21(4):196-200. doi:10.3121/cmr.2023.1833 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | both_with_link | CLM-0003, CLM-0005, CLM-0006 |
| S | Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | both_with_link | CLM-0003, CLM-0007, CLM-0009 |
| S | Chronic kidney disease stage G3a A1 | active | confirmed | active | |
| S | Essential hypertension | active | confirmed | active | |
| S | Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | active | |
| S | Acute gout flare of the left knee, crystal-proven, during urate-lowering titration; resolved | resolved | confirmed | active | CLM-0003 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1782-03-02 | Urate [Mass/volume] in Serum or Plasma | 9.1 mg/dL (high) Reference 3.5-7.2 mg/dL |
http://loinc.org · 3084-1 |
| S | 1782-03-02 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1782-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1782-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1782-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 1782-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.36 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1782-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 54 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1782-03-02 | Glucose [Mass/volume] in Serum or Plasma | 98 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1782-03-02 | Calcium [Mass/volume] in Serum or Plasma | 9.5 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 1782-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 1782-03-02 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 pg/mL Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 1782-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 1782-03-02 | Hemoglobin [Mass/volume] in Blood | 14.2 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 1782-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1782-03-02 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 mg/dL (high) Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 1782-03-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 1782-03-02 | Albumin/Creatinine [Mass Ratio] in Urine | 18 mg/g Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 1782-03-02 | pH of Urine | 5.2 [pH] Reference 4.5-8 [pH] |
http://loinc.org · 2756-5 |
| S | 1782-03-02 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 12 /[HPF] (high) Reference <=2 /[HPF] |
http://loinc.org · 13945-1 |
| S | 1782-03-02 | Lead [Mass/volume] in Blood | 3.1 ug/dL Reference <=3.5 ug/dL |
http://loinc.org · 5671-3 |
| S | 1782-03-02 | International Prostate Symptom Score [IPSS] | 16 | http://loinc.org · 80976-4 |
| S | 1782-03-02 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.2% | http://loinc.org · 85624-5 |
| S | 1782-03-02 | Kidney failure 5-year risk [Likelihood] by KFRE | 0.6% | http://loinc.org · 85625-2 |
| S | 1782-03-30 | Urate [Mass/volume] in Serum or Plasma | 7.6 mg/dL (high) Reference 3.5-7.2 mg/dL |
http://loinc.org · 3084-1 |
| S | 1782-03-30 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1782-03-30 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1782-03-30 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1782-03-30 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 1782-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.34 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1782-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 55 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1782-03-30 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1782-03-30 | US Urinary bladder Volume post void | 160 mL (high) Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 1782-03-30 | Maximum Urine flow by Uroflowmetry | 8.5 mL/s (low) Reference >=10 mL/s |
http://loinc.org · 80519-2 |
| S | 1782-03-30 | International Prostate Symptom Score [IPSS] | 16 | http://loinc.org · 80976-4 |
| S | 1782-05-18 | Urate [Mass/volume] in Serum or Plasma | 6.4 mg/dL Reference 3.5-7.2 mg/dL |
http://loinc.org · 3084-1 |
| S | 1782-05-18 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1782-05-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1782-05-18 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1782-05-18 | Urea nitrogen [Mass/volume] in Serum or Plasma | 20 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 1782-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1782-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 56 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1782-05-18 | Glucose [Mass/volume] in Serum or Plasma | 95 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1782-05-18 | pH of Urine | 5.3 [pH] Reference 4.5-8 [pH] |
http://loinc.org · 2756-5 |
| S | 1782-05-18 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 /[HPF] Reference <=2 /[HPF] |
http://loinc.org · 13945-1 |
| S | 1782-05-18 | Volume of 24 hour Urine | 1.45 L/(24.h) (low) Reference At least 2.5 L a day for stone prevention |
http://loinc.org · 3167-4 |
| S | 1782-05-18 | Urate [Mass/time] in 24 hour Urine | 840 mg/(24.h) (high) Reference <=800 mg/(24.h) |
http://loinc.org · 3087-4 |
| S | 1782-05-18 | Citrate [Mass/time] in 24 hour Urine | 410 mg/(24.h) Reference >=320 mg/(24.h) |
http://loinc.org · 6687-8 |
| S | 1782-05-18 | Calcium [Mass/time] in 24 hour Urine | 180 mg/(24.h) Reference <=250 mg/(24.h) |
http://loinc.org · 6874-2 |
| S | 1782-05-18 | US Urinary bladder Volume post void | 35 mL Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 1782-05-18 | International Prostate Symptom Score [IPSS] | 6 | http://loinc.org · 80976-4 |
| S | 1782-09-14 | Urate [Mass/volume] in Serum or Plasma | 5.4 mg/dL Reference 3.5-7.2 mg/dL |
http://loinc.org · 3084-1 |
| S | 1782-09-14 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1782-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1782-09-14 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 26 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1782-09-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 1782-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1782-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 56 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1782-09-14 | Glucose [Mass/volume] in Serum or Plasma | 97 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1782-09-14 | pH of Urine | 6.3 [pH] Reference 4.5-8 [pH] |
http://loinc.org · 2756-5 |
| S | 1782-09-14 | US Urinary bladder Volume post void | 30 mL Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 1782-09-14 | International Prostate Symptom Score [IPSS] | 5 | http://loinc.org · 80976-4 |
| S | 1782-07-06 | Urate [Mass/volume] in Serum or Plasma | 5.9 mg/dL Reference 3.5-7.2 mg/dL |
http://loinc.org · 3084-1 |
| S | 1782-07-06 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1782-07-06 | Creatinine [Mass/volume] in Serum or Plasma | 1.33 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1782-07-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1777)/1.73 sq M | 55 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1782-07-06 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1782-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1782-10-19 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 1782-10-19 | Total score [AUDIT-C] | 4 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1782-03-02 | Body height | 175 cm | 8302-2 | S |
| 1782-03-02 | Body weight | 96 kg | 29463-7 | S |
| 1782-03-02 | Body mass index (BMI) [Ratio] | 31.3 kg/m2 | 39156-5 | S |
| 1782-03-02 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 1782-03-02 | Diastolic blood pressure | 86 mm[Hg] | 8462-4 | S |
| 1782-03-02 | Heart rate | 74 /min | 8867-4 | S |
| 1782-03-02 | Respiratory rate | 16 /min | 9279-1 | S |
| 1782-03-02 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1782-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1782-03-30 | Body height | 175 cm | 8302-2 | S |
| 1782-03-30 | Body weight | 95.4 kg | 29463-7 | S |
| 1782-03-30 | Body mass index (BMI) [Ratio] | 31.2 kg/m2 | 39156-5 | S |
| 1782-03-30 | Systolic blood pressure | 138 mm[Hg] | 8480-6 | S |
| 1782-03-30 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 1782-03-30 | Heart rate | 70 /min | 8867-4 | S |
| 1782-03-30 | Respiratory rate | 16 /min | 9279-1 | S |
| 1782-03-30 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1782-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1782-05-18 | Body height | 175 cm | 8302-2 | S |
| 1782-05-18 | Body weight | 94.6 kg | 29463-7 | S |
| 1782-05-18 | Body mass index (BMI) [Ratio] | 30.9 kg/m2 | 39156-5 | S |
| 1782-05-18 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 1782-05-18 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 1782-05-18 | Heart rate | 72 /min | 8867-4 | S |
| 1782-05-18 | Respiratory rate | 16 /min | 9279-1 | S |
| 1782-05-18 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1782-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1782-09-14 | Body height | 175 cm | 8302-2 | S |
| 1782-09-14 | Body weight | 93.2 kg | 29463-7 | S |
| 1782-09-14 | Body mass index (BMI) [Ratio] | 30.4 kg/m2 | 39156-5 | S |
| 1782-09-14 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 1782-09-14 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 1782-09-14 | Heart rate | 68 /min | 8867-4 | S |
| 1782-09-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 1782-09-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1782-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1782-07-06 | Body height | 175 cm | 8302-2 | S |
| 1782-07-06 | Body weight | 94 kg | 29463-7 | S |
| 1782-07-06 | Body mass index (BMI) [Ratio] | 30.7 kg/m2 | 39156-5 | S |
| 1782-07-06 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 1782-07-06 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 1782-07-06 | Heart rate | 84 /min | 8867-4 | S |
| 1782-07-06 | Respiratory rate | 16 /min | 9279-1 | S |
| 1782-07-06 | Body temperature | 37.7 Cel | 8310-5 | S |
| 1782-07-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1782-10-19 | Body height | 175 cm | 8302-2 | S |
| 1782-10-19 | Body weight | 93 kg | 29463-7 | S |
| 1782-10-19 | Body mass index (BMI) [Ratio] | 30.4 kg/m2 | 39156-5 | S |
| 1782-10-19 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 1782-10-19 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 1782-10-19 | Heart rate | 66 /min | 8867-4 | S |
| 1782-10-19 | Respiratory rate | 14 /min | 9279-1 | S |
| 1782-10-19 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1782-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: semi-retired diplomat, author, and inventor; ran a printing business when young and set hot-metal type by hand for years
- S Never smoker; wine with dinner most days, two glasses on social evenings; rich meals with meat and fish at frequent dinners
- S Mostly sedentary: reads and writes for long hours; plays chess in the evenings; rides in a car rather than walking
- S Lives in his own house with family nearby; a housekeeper helps several days a week
- S Supports: family nearby, a wide circle of friends and correspondents, and a regular chess partner
Functional status
- S At intake, flares stop him walking for a week at a time, and jolting car rides and long walks bring on bladder pain
- S Walking 30 minutes most days and travelling without urinary pain by the six-month review
Mental status
- S Alert, witty, and curious; asks for the evidence behind each recommendation
- S Mood cheerful; cognition intact
Allergies and medications
Allergies
- S No known allergy
Medications
- S Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily
- S Losartan 50 mg oral tablet, one tablet by mouth daily
- S Allopurinol 100 mg oral tablet, one tablet by mouth daily
- S Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily
- S Allopurinol 300 mg oral tablet, one tablet by mouth daily
- S Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day
- S Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery
- S Atorvastatin 20 mg oral tablet, one tablet by mouth daily
- S Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals
- S Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 days
Procedures and immunizations
Procedures
- S Non-contrast low-dose CT of the abdomen and pelvis: single 2.6 cm bladder stone of about 420 Hounsfield units, suggesting uric acid; no kidney or ureteric stones; no hydronephrosis; enlarged prostate
- S 12-lead electrocardiogram: sinus rhythm, no left ventricular hypertrophy
- S Uroflowmetry: maximum flow 8.5 mL/s with a voided volume of 210 mL
- S Bladder ultrasound for post-void residual: 160 mL
- S Office flexible cystoscopy: single large bladder stone, trabeculated bladder, obstructing enlarged prostate with a median lobe, no bladder tumor
- S Transurethral laser cystolitholapaxy; stone analysis 100 percent uric acid
- S Transurethral resection of the prostate at the same operation; pathology benign prostatic hyperplasia
- S Arthrocentesis of the left knee: 25 mL of cloudy yellow fluid; needle-shaped, negatively birefringent crystals; Gram stain negative; culture later showed no growth
Immunizations
- S 1781-10-08: High-dose influenza vaccine, 1781-1782 season
- S 1779-11-06: Pneumococcal conjugate vaccine PCV20
- S 1778-04-11: Recombinant zoster vaccine, two-dose series completed
- S 1774-09-17: Tdap vaccine
- S 1782-10-19: High-dose influenza vaccine, 1782-1783 season
- S 1782-10-19: Respiratory syncytial virus vaccine, single dose
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1724: Occupational exposure to heated type metal as a compositor in London, with an obscure pain in the bones of the hand; he stopped heating the type (CLM-0002)
- D February 1727 (1726/7 Old Style): Pleurisy that very nearly carried him off (CLM-0010)
- D 1735: Severe pleurisy ending in an abscess of the left lung, with full recovery (CLM-0011)
- D October 22, 1780: Gout attack at midnight, recorded in his Dialogue between Franklin and the Gout (CLM-0005)
- D Winter of 1780 to 1781: Long and severe fit of gout through the winter, leaving him weakened (CLM-0006)
- D About 1781: First symptoms of the calculous complaint (bladder stone) (CLM-0007)
Family history
- D father: Died in 1744 at 89; no illness before his last; cause not recorded in the cited source
- D mother: Died in 1752 at 85; no illness before her last; cause not recorded in the cited source
- D natural son: Died in 1736 at four of smallpox
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Serum urate below 6 mg/dL on allopurinol by the six-month review | 1782-09-14 | completed | Serum urate 5.4 mg/dL on allopurinol 300 mg |
| Bladder stone removed and comfortable voiding with a normal post-void residual | 1782-05-18 | completed | Stone removed; IPSS from 16 to 6; residual 35 mL |
| No gout flare for six months after starting urate-lowering therapy | 1782-09-14 | active | Not met: one knee flare in July while urate was still above target; none since |
| Blood pressure below 130/80 without dizziness | 1782-09-14 | completed | 128/76 mmHg on losartan |
| Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.5 | 1782-09-14 | active | Urine pH 6.3 on potassium citrate; home measuring jug shows about 2.3 L a day |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Start allopurinol 100 mg daily and raise it by 100 mg every 2 to 5 weeks until serum urate is below 6 mg/dL; HLA-B*58:01 testing is not indicated, because he is not of Southeast Asian or African ancestry | completed | GL-ACR-GOUT-2020 |
| Colchicine 0.6 mg daily for three to six months as flare prophylaxis; treat flares with a short prednisone course or extra colchicine, and avoid NSAIDs because of chronic kidney disease | completed | GL-ACR-GOUT-2020, GL-CMID-2026 |
| Replace hydrochlorothiazide with losartan, which lowers blood pressure and slightly lowers urate; check potassium and creatinine 2 to 4 weeks after starting | completed | GL-ACR-GOUT-2020, GL-CMID-2026, GL-ACC-HTN-2017 |
| Urology referral to confirm and remove the bladder stone, look for bladder outlet obstruction and other causes of hematuria, and advise on stone prevention | completed | GL-AUA-STONE, GL-EAU-UROLITH, GL-AUA-BPH |
| Uric acid stone prevention: fluids for a urine output of at least 2.5 L a day, potassium citrate to a urine pH of 6.0 to 6.5, stone analysis, and a 24-hour urine collection | completed | GL-AUA-STONE, GL-EAU-UROLITH |
| CMID kidney and blood pressure monitoring: blood pressure every visit; eGFR and urine albumin yearly at G3a A1; calcium, phosphate, and PTH at baseline; hemoglobin and the kidney failure risk equation yearly; statin for age over 50 with eGFR below 60; medication review for NSAIDs every visit | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 |
| Limit alcohol, especially beer and spirits, and purine-rich meat, organ meat, and shellfish; avoid sugar-sweetened drinks; aim for gradual weight loss and daily walking | completed | GL-ACR-GOUT-2020 |
Planned encounters
- 1782-03-02 — Primary care visit for recurrent gout flares and painful, interrupted urination with blood in the urine (ENC-001)
- 1782-03-30 — Four-week gout and blood pressure review, with urology consultation for a bladder stone (ENC-002)
- 1782-05-18 — Review four weeks after stone removal and prostate resection, with urate titration and stone metabolic evaluation (ENC-003)
- 1782-07-06 — Same-day sick visit for a hot, swollen left knee (ENC-005, unscheduled)
- 1782-09-14 — Gout, stone prevention, kidney, and blood pressure review at about six months (ENC-004)
- 1782-10-19 — Subsequent annual wellness visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Care-plan review)
- Progress note 06 — Annual Wellness Visit, Subsequent
- Urology referral
- Urology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Progress note 06 — Annual Wellness Visit, Subsequent (XML)
- Urology referral (XML)
- Urology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check allopurinol titration in stage 3a CKD, colchicine with atorvastatin, potassium citrate with losartan, and the two titration and potassium-check deviations recorded. |
| provenance review | not_started | Gutenberg editions of his letters, works, and autobiography, two PubMed abstracts, and an American Battlefield Trust biography logged; Founders Online could not be fetched (bot challenge). Lead poisoning is graded R, possible. |
| safe messaging review | not_started | No behavioral-health content; laudanum use in his last year is recorded only as historical fact; death recorded without graphic detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.